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SCIENCE AND TECHNOLOGY POLICY: A SCIENTIST'S VIEW
FLOYD BLOOM, M.D.*
For the purposes of full disclosure, I am the chairman of the department
neuropharmacology at the Scripps Research Institute. Since May of 1996, I
have been the Editor-in-Chief at Science Magazine, which we like to tell
people is the most widely read general scientific magazine in the world. I also
consult for many biotechnology companies, as well as for the federal
government and pharmaceutical companies. If you infer anything from this
Article, I at least want you to know the perspective from which I am coming.
Scientists today are interested in the views expressed in this publication
because we are both frustrated and under the pressures of extreme competi-
tion. There is competition between scientists for having clever ideas, and
there is competition between the funders of science for who gets the rights
to develop our discoveries. Last week, Science Magazine's news section
described a new biomedical research center to be funded in San Diego by
monies coming from one of the corporations within the tobacco industry.1
We felt obliged to examine this set of issues because it raised anew the issue
of whether funds from nontraditional commercial sources would in some way
diminish the quality of the research being funded; and whether by putting a
* Chairman of the Department of Neuropharmacology at the Scripps Institute, La Jolla,
California and Editor-in-Chief of Science. Dr. Bloom received his M.D. degree cum laude from
Washington University School of Medicine in St. Louis, and his A.B. cum laude from Southern
Methodist University. After completing his internship and first year residency at Barnes Hospital
in St. Louis, Dr. Bloom began his research career as a Research Associate of the National
Institutes of Mental Health (NIMH) at St. Elizabeth's Hospital, Clinical Neuropharmacology
Research Center, Washington D.C., while also serving as an Associate in Physiology at George
Washington University School of Medicine. Dr. Bloom then accepted a U.S. Public Health
Service Special Post-Doctoral Fellowship at Yale University School of Medicine, following
which he joined the faculty of Yale University School of Medicine. He was Associate Professor
of Pharmacology at Yale prior to accepting the position of Chief, Section on Cytochemical
Pharmacology at the NIMH, St. Elizabeth's Hospital. Dr. Bloom was Acting Director of the
Division of Special Mental Health Research Programs for the NIMH when he went to San Diego
as Director of the Arthur V. Davis Center for Behavioral Neurobiology at The Salk Institute.
In 1983, Dr. Bloom joined Scripps as Director of the Division of Preclinical Neuroscience and
Endocrinology. He became a member of the National Academy of Sciences in 1977. His
numerous other awards and honors include the A.E. Bennett Award, the A. Cressy Morrison
Award, the Arthur S. Fleming Award, the Mathiled Solowey Award, the Jansen Award in Basic
Sciences, the Pasarow Award in Neuropsychiatry, the Hermann von Helmholtz Award, the
Pythagora Prize, and honorary degrees from Southern Methodist University, Hahnemann
University, and the University of Rochester. In addition to his leadership role in the American
Association for the Advancement of Science as Editor-in-Chief of Science, he is a past-president
of the American College of Neuropsychopharmacology, former Chairman of the Neurobiology
Section of the National Academy of Science and a foreign member of the Royal Swedish
Academy of Science. Dr. Bloom has been invited to fill many distinguished lectureships,
including the Decade of the Brain Lecture for the Society for Neuroscience. He serves on
numerous editorial advisory boards and is author or coauthor of 19 books and monographs and
597 other publications.
1. Jon Cohen, Tobacco Money Lights Up a Debate: Tobacco-Industry Support of
Supposedly Independent Research, 272 ScIENcE, Apr. 26, 1996, at 488.
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lot of money into an important molecular area of medical research, we would
be in some way misleading the public as to the dangers of the product that
provided the funds for the research in the institutions.
If you read that news article written by Jon Cohen, Science's reporter
from Southern California, you will find a very balanced coverage of the
degree to which fair-minded people strongly disagree on those sets of issues.
Therefore, as scientists trying to exist in a highly competitive atmosphere, we
must always be aware of the fact that funds from any source are not
necessarily equal in their value as to what might come of them. You will
also find that there were some very accomplished scientists who felt coerced
into taking tobacco money because their regular research grants had dried up.
Some of those scientists went on to win Nobel prizes.2 So, in my view, such
funding can't be completely bad.
The federal commitment for the support of the National Institutes of
Health's (NI) 3 basic research budget has experienced a slow, but steady,
rise over the last several years. The problem is that there has been a rapid
increase in the number and the quality of investigator initiated research
grants. This has strongly compromised that modestly growing NIH budget.
This means that scientists spend an awful lot of their time writing grant
applications and experiencing the frustration that, even though they have
received scores far better than any scores they have ever received before, they
are unable to secure funding for their research grants. It is difficult enough
for a senior scientist to try to buck these trends, but it is extremely demoraliz-
ing for our young people. In my view, it is the young people on whom we
have to rely for the future of this research field.
Over the last decade or so, Congress has tinkered with the NIH's budget,
forcing first the aspect of the total numbers of grants and then another aspect,
the average duration of grants (as well as a variety of other manipulations),
in an effort to make research dollars stretch farther. It generally has not
worked. In the face of the Republican Congress's zeal to balance the budget,
the NIH supporters were very pleased that we were able, thanks to Congress-
2. Stanley Cohen, of Vanderbilt University; Baruj Benacerraf of the Dana-Farber Cancer
Institute; and Harold Varmis, Director of the National Institutes of Health. Id. at 490-496.
3. The NIH is a federal agency that underwrites research in its own laboratories, as well as
in those at private and public institutions by awarding grants and contracts.
In the area of biotechnology, NIH-supported research can be divided in two
categories. The first is basic research directly related to biotechnology, which includes
recombinant DNA techniques; gene mapping and DNA sequencing; isolation,
separation, and detection of DNA; the creation of hybridomas; the production of
monoclonal antibodies; protein engineering; production of antibody-tom chimeras
(immunotoxins); and the computer analysis of DNA and protein sequences. the
second category relates to the broad research underlying biotechnology and refers to
studies in the fields of genetics, cellular and molecular biology, biological chemistry,
biophysics, immunology, virology, macromolecular structure, and pharmacology.
U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, BIOTECHNOLOGY IN A GLOBAL
ECONOMY 249 (1991).
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man Porter's4 leadership, to get a modest 5.5% spending increase in the 1996
Budget. That is a very unique growth in this year's fiscal budget for science,
but it is not very good. It barely allows us to maintain an adequacy with
inflation-and in biomedical research, inflation is considerably higher than
it is for the general public.
It is not only frustrating for scientists who have to compete, but it is
frustrating for the public who wants the scientists to succeed. There are
many important insoluble problems that we face today and the biological
sciences offer an unprecedented opportunity for significant advances in the
understanding of the molecules responsible for both health and disease.
Scientists are as frustrated by their inability to proceed as they are frustrated
by the intensity of the competitions that we face.
Now I work at the Scripps Research Institute. Scripps has been a leader
in trying to find innovative ways of protecting our faculty against some of
these rigors and variations in federal support. Thus, I write my next remarks
not on behalf of any formal statement of our Scripps leadership, but really as
a faculty member who was deeply involved in examining the various
contracts we have implemented with our current and our future research
partners. At Scripps, we view ourselves as a small, private research
organization. In order for us to compete successfully for the research
opportunities that our faculty face, we found alternative sources of funding
to be a very desirable feature; but it bothered many of our faculty to undergo
these kinds of corporate relationships. My friend, Carleton Gajdugek, the
Nobel prize winner5 who currently has his own problems,6 has noted that
almost all modem science requires patronage. All patronage requires wealth
and power on the part of the patron, but the accumulation of wealth or power
implies, to a moralist, an underlying evil. This applies whether the patron be
the church, government, foundations, academic societies, or private universi-
ties. Almost certainly, the implied evil of corporate sponsorship could extend
to commercial industries' involvement in academic research-but I don't
really think it will.
Industry plays a very important role, and an increasingly important role,
in the health sciences. Although corporate America's annual investment in
research exceeds that of the NIH and biomedical research, most of those
funds go into research and development and the development of the
technologies. The apparent commercial potential for genetically engineered
medications has attracted considerable private investment money in the
general industry and it is a pleasure that San Diego has become a leader in
making this common bridge between academic, scientific laboratories, and
industry. It has been estimated that of the $700 billion health-related
industries (pharmaceuticals, biotech, medical devices and instruments) spend
4. John F. Porter (R-Ill.).
5. Nobel prize in medicine, awarded 1976.
6. See Nobel Winner's Trial Seated for October, WASH. Tms, June 4, 1996, at C6.
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each year little more than 10% of those research funds are actually spent
outside the companies' own research labs at either universities or private
research institutes such as Scripps. When the Scripps Research Institute
(TSRI) ran afoul of public opinion a couple of years ago, we were trying to
develop long-term relationships with a new corporate collaborator.7 I found
it quite surprising that many of my scientific colleagues remained blissfully
unaware of the federal statutes that dealt with the ownership of intellectual
properties that arise from federally funded research projects.
When I began my grant-seeking research career in the mid-1960s, all
patents that could have been derived from federally funded research were
deemed to be owned by the government and all of us grant applicants had to
forfeit our rights and relinquish our interest in anything we might discover.
Although very few of us discovered anything that was able to be developed,
a few things were developed. That changed in 1980, when President Carter
enacted the Bayh-Dole Act or the Patent & Trademark laws amendment of
1980,8 which gave first preference for the licensing of federally funded
inventions to non-profit organizations and small business firms. In 1983,
President Reagan extended the licensing opportunity to all sizes of business,
as an incentive to private industry to commercialize investments developed
with federal funds.9 Both of these pieces of legislation extended the earlier
Stevenson-Wyldler Technology Innovation Act,"° which had also attempted
to facilitate the conversion of research into useful public purposes.
The Technology Innovation Act has encouraged cooperation between the
academic establishment and industry, and has helped in technology transfer.
It has also helped in personnel exchanges, joint research projects, and things
that called for a comprehensive national policy to enhance technological
innovation for commercial and public purposes. The combined effect of these
pieces of legislation is that universities and research institutions are the
owners of the federally funded research and the results of that research.
Furthermore, they are legally bound to seek prompt development of these
discoveries, and failure to do so could result in reinstatement of the
government's ownership for purposes of such development.
As you know, there are at least five ways in which we in scientific
academic labs can collaborate with industrial relationships in the health
sciences. We can have what we think we have forming between Scripps and
Sandoz," which is an academic industry training relationship in which the
industry funds trainees for academic settings. In turn, the academic settings
provide educational expertise for the industrial employees. We look forward
7. See Leslie Helm, Foreign Firms with Deep Pockets Test U.S. Labs, L.A. TIMES, Nov. 6,
1991, at DI.
8. 35 U.S.C. § 3200 (1994) superseded by 15 U.S.C. § 3710 (1994).
9. 15 U.S.C. § 3710(a) (1994).
10. 15 U.S.C. §§ 3701-3717 (1994).
11. Sandoz will soon become Novartis, as it has now merged with the Ciba-Geigy
Corporation.
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to this kind of exchange of personnel. We can have grants or contracts from
industry to members of a university lab. We can have what many in the
industry have already experienced: consultanships by individual faculty
members to advise specific companies in their areas of interest. We can sell
or license our academic patents to the industry, and we can participate, either
the institution or individual faculty members, in establishing and owning new
companies. That is what CONNECT 2 is really all about in this area.
In the views of many medical economists,13 academic industrial
relationships can have many potential benefits for the academic institutions
who choose this route to supplement their research funding base. For
example, TSRI is a private, self-standing research institution. Income from
our endowment amounts to less than 10% of our annual operating budget.
So for our leadership, our corporate agreements are our means to strengthen
the economic stability of our institution, buffer ourselves against the
increasing pressures on federal support for health sciences research, and
provide a means to renew our infrastructure and faculty recruitment.
There are also substantial perceived risks to such relationships. Among
the most frequently listed potential problems are the possible compromise to
the institution and their faculty in the selection of their research directions,
and the potential for investigator bias in the interpretation of research results
resulting from projects in which the institution or the faculty member might
have a proprietary interest. Potential conflicts of interest, to a certain extent,
contaminate or shroud many of these relationships. There is no easy way to
eliminate them completely, but through candid disclosures of all our
relationships when we sit down at a table to enter into agreements, I think we
can eliminate some of the anticipated onerousness of such disclosing actions,
even though it may have prevented many other scientists and their institutions
from getting into this particular kind of relationship.
Given the need for a dependable funding base that can sustain the
institution and nurture its growth, we looked at all the opportunities that were
available to us and recognized two of them. On the one hand, we could take
the course followed by many academic institutions and simply spin-off each
patentable discovery of potential, practical marketability into a subsidiary that
could be funded by venture or industrial capital, in which we or our elite
scientists might then play significant ownership and management roles. There
is potential for the individuals involved to reap sizable financial rewards but
it neglects to provide any support for the broader institutional community or
the institution that contributed to the environment in which the discoveries
were made. On the other hand, as Richard Lerner (President of TSRI)
reasoned, we could establish exclusive relationships with a single company
and work with them to maximize the potential of our discoveries in the
12. CONNECT is the Program on Technology and Entrepreneurship at the University of
California at San Diego Extension.
13. See Robert Bohrer, Address to the 1994 Mid-Winter Institute Thursday Luncheon (Jan.
27, 1994), in AIPLA BULL., Mar.-Apr. 1994, at 309.
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ultimate commercial marketplaces. This was the course that we originally
adopted 13 years ago, when Dr. Frank Dixon (founding Director of Scripps
Research) negotiated the agreement with Johnson & Johnson, and that is the
course that we will be taking with Sandoz starting in January of 1997.
Our agreement with Sandoz recognizes at the outset that our purpose in
establishing this relationship is to cooperate in making available to the public
the benefits of discoveries, inventions, and research of TSRI applicable to the
fields in which the company and its affiliates have business interests. In the
current period of our relationship with Johnson & Johnson, and in our future
relationship with Sandoz, there are going to be faculty members who feel that
their discoveries are not being covered by these agreements. And, in fact,
when we were able to sit down with Bernadine Healy's"4 lawyers and then
Dr. Varmus' lawyers, we were able to carve out areas to which Sandoz could
not have rights. In those areas, our faculty members can still go out and
establish relationships in terms of CONNECT.
Ray Kahn 5 was our first liaison trying to find venture capitalists who
might be interested in starting these companies. These new approaches that
you have now will facilitate those types of arrangements. They have to be
there; there is always going to be someone who does not recognize what the
scientist thinks is the greatest thing since sliced bread or vine-ripened
tomatoes. The problem is that it takes an awful lot of the scientists' time to
do that and if they are as committed to their original research discovery as
they are to getting the new company funded, they cannot do them both. So,
having an organization such as CONNECT is an irreplaceable resource that
allows us to proceed.
It is awfully hit-or-miss, and certainly something that could help young
scientists understand the business side of their discoveries' exploitations. This
is a critical element in making real what we all perceive to be the possibilities
of the kind of research that we are doing. Obviously, what is good for TSRI
is not necessarily good for everybody. Institutions with extensive endow-
ments, or with dependable budgets provided by state legislatures, might
logically have other ways in which to carry their future.
Steven Paul, who is a friend of mine, was formerly the director of
Intramural Research for the National Institutes of Mental Health (NIMH),
where I spent many of my own formative years "growing up" in research.
He left the NIMH intramural program about three years ago to become the
director of CNS research for the Eli Lilly Company of Indianapolis
(sometimes referred to as the house of Prozac). Just before he left the federal
government, he wrote an editorial for The Wall Street Journal, in which he
declared that government-sponsored basic research cannot produce the new
medications needed to treat diseases, such as AIDS, Alzheimer's, cancer, and
schizophrenia-diseases which require costly long-term hospitalizations, but
14. Dr. Bernadine Healy is a former director of NIH.
15. Ray Kahn oversees technology transfer at Scripps Institute and Research Clinic.
[Vol. 33
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are essentially untreatable. He said that the skills and personnel required to
convert basic scientific discoveries on the nature of these diseases into
medication or preventive measures are not well represented in the pool of
basic research scientists. He then felt compelled to go to private industry,
where he could work on exactly that, and he felt that such treatments to treat
these devastating illnesses could be found and developed only through private
entrepreneurship. That is a very strong statement, but if you recognize the
history of the medication represented by Prozac, you will find perhaps ironic,
and perhaps poignant, the fact that the action for this class of drugs, which
are amine re-uptake inhibitors,' 6 was in fact discovered in the intramural
program at the NIMH in 1965 by Julius Axelrod, about 5 years before he
won the Nobel prize for completely different reasons. 7
It took many drug companies years to recognize what their goal was in
developing Prozac. To the Eli Lily company's credit, in order to eliminate
the perceived side effects of this class of compounds (you may have heard of
them referred to as tricyclic antidepressants) which have significant cardiovas-
cular effects,'" they decided from their in-house research to focus on simply
blocking the re-uptake of serotonin. To achieve a thousand-fold increase in
specificity on the amine transporter for serotonin, well before this molecule
had ever been cloned, they used classic pharmacological development
techniques, structure activity relationships, and came up with a compound that
today has the majority of the market of tricyclic antidepressants. Thanks in
part to its specificity of action, and the consequences of that combined with
a highly specific drug, you have very few serious side effects.' 9 That
required of them at least 15 years of research after they recognized what their
target was. Today, they have about four years of patent protection left and
I can tell you from a recent visit, they are avidly pursuing the sons and
daughters of Prozac even as we speak.
To give you another anecdote from my experience at Science, on the 28th
of July last year, we reported three separate research papers on a newly
discovered peptide hormone that has been named Leptin.2" Leptin has the
capacity to reduce the weight of genetically obese rodents and is thought to
be a possible new pathway to control obesity in human beings.
16. Amine Re-uptake Inhibitors are an older type of antidepressant that use an amine instead
of serotonin.
17. Julius Axelrod won the Nobel Prize for medicine and physiology for research on
neuronal transmission in 1970.
18. The Cardiovascular side effects from antidepressant drugs include significant blood
pressure changes, conduction disturbances, and arrhythmias. Cardiovascular Safety in Depressed
Patients: Focus on Vanlafaxine, 56 J. CLIN. PSYCHIATRY 574 (1995).
19. Typical side effects for this class of drugs include headache, nausea, and sexual
dysfunction. J.M. Andrews & C.B. Nemeroff, Contemporary Management of Depression, 97
AM. J. MED. 24S-32S (1994).
20. Arthur L. Campfield, et al., Recombinant Mouse OB Protein: Evidence for a Peripheral
Signal Linking Adiposity and Central Neural Networks, 269 SCIENCE, July 28, 1995, at 546.
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At Science, we normally operate under an embargo rule: We inform the
press of the contents of an issue, eight days before we release the forthcoming
issue. We give them this opportunity in advance so that the reporters,
regardless of the media in which they work, will have the time to do the
diligent background that is required for them to file their own independent
scientific reports on these discoveries. That occurred in this case; however,
in complete disregard of our press embargo, a biotechnology analyst with a
large New York brokerage company, who had been asked by one of the
reporters for the financial implications of this new discovery, sent out alerts
to thousands of the firm's customers alerting them of the possible financial
benefit of these new papers. This triggered a small run-up in the stock prices
of one of the three companies, each of which had patents pending on the
applications of this new natural hormone.
In my view, these customers who bought in on the news of our Science
report were not well served by this extremely enthusiastic, overrated
recommendation. The Leptin's payoff, should it ever come, is likely to be
years, if not decades, into the future. Leaking advance information some
forty-eight hours before the rest of the scientific public knew about it,
provided only an illusory and quite modest financial gain.
Most of the scientists active today are really only interested in pursuing
their curiosity. I think that if you ask people if they would rather have a
lifetime of grant support or win a million dollars in their own company, most
of them would opt for having consistent, continuous research support to fuel
their ability to pursue curiosity. A vital research environment, and that is
what we sought to protect with our corporate relationship, makes an
environment where there is a large number of curiosity-driven investiga-
tors-and it is their skills that create the innovative technologies and prece-
dent-breaking rules through which the operations of living organisms are
being understood at the molecular level.
Those who are equally interested in applying this technology to important
health-related opportunities recognize that innovative science is the best
starting point for innovative therapeutic developments. Since one cannot
legislate or plan discoveries, we at Scripps feel that a funding partnership
with biotech to maximize the new applications that may emerge from our
work can best be served by a system of funding support that can nurture
individuals, refine their discoveries, and then at the proper time hand them
over to equally skilled colleagues who can carry them forward into the
marketplace. Academic scientists are frustrated in this current environment
because of the extremely competitive funding times. The reason for this is
that we are at just that point in the scientific evolution of our research when
the knowledge from our distributed intelligence, whether it is molecular
genetics, cell biology, combinatorial chemistry, or even the linkages between
genetics and epidemiology and preventive medicine, are at their peak of
[Vol. 33
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potential-the fruits of the mind that Commissioner Lehman addresses in his
article.2 '
This frustration over being unable, in a timely manner, to harvest the
fruits of our past investments in research makes me want to ask if there is no
better way to do this. Are we so unimaginative that we accept meekly the
idea that the only way to balance past budgetary deficits is to cut-off the
small wedges of discretionary funding that sustain our research enterprise?
The San Diego community may have recalled the article written by the
Commissioner of the Port District in the Sunday paper about three Sundays
ago,22 in which he noticed that when he came here, everything was in
decline and he decided he could cut his budget back to live within the budget
they had given him or take a chance and try some adventures that would
create new jobs and new skills. I think he has done a remarkable job in
restoring the shipbuilding industry to this area, bringing tourism back, and
creating job opportunities. And that is what I think biotechnology and
science can do together.
It is failure to understand the nature of fundamental research within the
federal government that really puts us in the position that we are in today.
My experiences in Washington so far, as editor of Science, tell me that we
are scarcely distinguished from other subsidies to other so-called "public
needs" seen by Congress in their attempts to maintain reelection. We are no
different to them from supporting gasoline prices or controlling them, or from
the falling costs of beef which require the government to buy $50 million
worth of beef to maintain the beef industry because the cost of grain is at the
highest it has ever been because we paid farmers not to plant the grain that
would have gone to feed the cattle. And when the cattle industry got their
$50 million relief, the pork, lamb, chicken and turkey industries rose, saying
that they had to buy that same grain too and shouldn't they have relief, which
then caused the salmon farmers of Alaska to note that they still have most of
last year's salmon crop frozen in their fisheries, and if the government
doesn't buy that up, the fishermen won't go out, which will cause lots of
unemployment, not to say ecological benefits somehow sinisterly perceived
that will affect future generations of salmon now breeding in the ocean.
We are no different to Congress than these industries who are asking for
artificial supports to maintain their livelihood. If our research momentum is
able to continue, I do not think that any single corporate sponsor or any
federal patron can absorb all of the opportunities that are available today. I
do not think that knowledge is a commodity whose supply and demand
should determine its value. And I do not think the role of the government in
fundamental research is simply to buffer the ups and downs of the supply and
demand in the pursuit of knowledge. I think that as Americans, we ought to
21. Bruce Lehman, Major Biotechnology Issues for the U.S. Patent & Trademark Office,
33 CAL. W. L. REV. 49, 60 (1996) (this volume).
22. Lawrence M. Killeen, Opportunities Abound on San Diego's Waterfront, SAN DIEGO
UNION Tam., Apr. 28, 1996, at G1.
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be able to ask who is to determine how healthy we should be and when we
should achieve that state of healthfulness. If we do not ask that, then we are
not going to spend our money on something that we as individuals and as a
society would consider the best appropriation of those funds.
We not only need to support basic scientific research, but also that
intermediate critical area that pushes the basic understanding closer to the
point at which privately funded research can convert basic knowledge into
drugs, diagnostics, or even preventive strategies into products for improved
health. In this political campaign season, some open-minded thinking could
well be investigated on why we must continue to invest in, and not subsidize,
health from basic research science through the chemistry and physics that
provide the diagnostics and the research instruments all the way to the
delivery of the products to our society.
Subsidies, not investments, to the health care insurance industry in the
form of non-taxable contributions amount to nearly $50 billion each year.
These subsidies contribute not at all to the investment in health research. The
industry needs to bear its share of continuing to provide funding for basic
scientific discovery. Scientists want to harvest and replant the fruits of the
human mind. Industry is a natural partner, and funding of technological
development has to remain a high priority to national good, at least in the
view of this scientist.
[Vol. 33
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